Breaking News

Tweet TWEET

Strong Sales, Diversified Portfolio, and R&D Progress Boost Growth - Research Report on Teva, Auxilium, Nektar, Anika, and

Strong Sales, Diversified Portfolio, and R&D Progress Boost Growth - Research
              Report on Teva, Auxilium, Nektar, Anika, and Vical

PR Newswire

NEW YORK, August 6, 2013

NEW YORK, August 6, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Teva
Pharmaceutical Industries Ltd. (NYSE: TEVA), Auxilium Pharmaceuticals (NASDAQ:
AUXL), Nektar Therapeutics (NASDAQ: NKTR), Anika Therapeutics, Inc. (NASDAQ:
ANIK), and Vical Incorporated (NASDAQ: VICL). Today's readers may access these
reports free of charge - including full price targets, industry analysis and
analyst ratings - via the links below.

Teva Pharmaceutical Industries Ltd. Research Report

On August 1, 2013, Teva Pharmaceutical Industries Ltd. (Teva) reported its
financial results for Q2 2013. Total revenues decreased 1.4% YoY to $4.9
billion. Net loss attributable to Teva was $452 million or $0.53 per diluted
share in Q2 2013, compared to net income of $863 million or $0.99 per diluted
share in Q2 2012. Commenting on the results, Jeremy Levin, Teva's President
and Chief Executive Officer, said, "Net revenue of $4.9 billion was in-line
with the previous quarter, and we are pleased with increased sales in our
Specialty franchise, as well as in our OTC business. In the short to mid-term,
we are especially excited by the positive momentum of our U.S. Generics
business, progression in our R&D portfolio, especially in the NTE franchise,
and by the expected launches of key generic and specialty medicines." The Full
Research Report on Teva Pharmaceutical Industries Ltd. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.analystscorner.com/r/full_research_report/e3a3_TEVA]

--

Auxilium Pharmaceuticals Research Report

On August 1, 2013, Auxilium Pharmaceuticals, Inc. (Auxilium) reported its
financial results for Q2 2013. Net revenues increased 28.5% YoY to $100.5
million. On a GAAP basis, net income was $57.1 million or $1.15 per diluted
share in Q2 2013, compared to net income of $7.7 million or $0.16 per diluted
share in Q2 2012. Commenting on the results, Adrian Adams, Chief Executive
President of Auxilium, said, "In the second quarter of 2013, Auxilium achieved
strong growth and record net revenues, and we are confident of achieving the
$20 million synergy target we have set for 2014 from the integration of
Actient. For the remainder of 2013 and beyond, we will continue to focus on
delivering excellence in execution with a new commercial structure and a
broader and more diversified product portfolio. We also look forward to the
upcoming PDUFA date for XIAFLEX for the treatment of Peyronie's disease and
are planning a potential launch in the U.S. in the fourth quarter, pending FDA
approval for this indication." The Full Research Report on Auxilium
Pharmaceuticals - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/86a4_AUXL]

--

Nektar Therapeutics Research Report

On July 30, 2013, Nektar Therapeutics (Nektar) announced the completion of
enrollment in its pivotal clinical study of etirinotecan pegol (NKTR-102) in
patients with metastatic breast cancer. The Company stated that the Phase 3
study (BEACON trial) is evaluating etirinotecan pegol versus a single-agent
treatment of physicians' choice for the treatment of locally recurrent
metastatic breast cancer. Robert Medve, M.D., Senior Vice President and Chief
Medical Officer of Nektar, said, "We recognize the high unmet need for new
treatment options in the metastatic breast cancer setting, particularly among
patients with HER2-negative breast cancer whose disease has progressed
following anthracycline, taxane and capecitabine therapies. The primary
endpoint in the BEACON study is survival and as we have previously announced,
we plan to conduct an interim futility analysis for the BEACON study in the
first quarter of next year with topline survival data to be available around
the end of 2014." According to Nektar, etirinotecan pegol is the first
long-acting topoisomerase I inhibitor designed to concentrate in tumor tissue
to provide sustained tumor suppression throughout the entire chemotherapy
cycle.The Full Research Report on Nektar Therapeutics - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.analystscorner.com/r/full_research_report/3421_NKTR]

--

Anika Therapeutics, Inc. Research Report

On July 31, 2013, Anika Therapeutics, Inc. (Anika) reported its financial
results for Q2 2013. Total revenue increased 6.1% YoY to $20.8 million. Net
income was $5.9 million or $0.40 per diluted share, compared to net income of
$3.7 million or $0.26 per diluted share in Q2 2012. Charles H. Sherwood,
Ph.D., President and Chief Executive Officer of Anika said, "Total revenue
grew 6% from the second quarter last year, driven by robust Orthobiologics
product demand. We are also very pleased with achieving a record second
quarter net income, which represents a 58% increase from the same period last
year. Our consistent delivery of product revenue growth and planned business
improvements has enabled us to drive bottom line growth and generate robust
cash flow." The Full Research Report on Anika Therapeutics, Inc. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.analystscorner.com/r/full_research_report/ae5d_ANIK]

--

Vical Incorporated Research Report

On August 1, 2013, Vical Incorporated (Vical) reported its financial results
for Q2 2013. Total revenues decreased approximately 7% YoY to $1.5 million.
According to Vical, this reflects ongoing reimbursements from Astellas Pharma
Inc. for expenses related to the development of ASP0113 (TransVax), Vical's
therapeutic vaccine designed to control cytomegalovirus (CMV) reactivation in
transplant recipients. Net loss was $9.9 million or $0.11 per diluted share,
compared to net loss of $7.9 million or $0.09 per diluted share in Q2 2012.
The Full Research Report on Vical Incorporated - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.analystscorner.com/r/full_research_report/ab7d_VICL]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

http://www.analystscorner.com/

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas - CONTACT PHONE: +1-310-496-8071 (North
America)
 
Press spacebar to pause and continue. Press esc to stop.